[Effect of autologous peripheral blood stem cell transplantation in 13 patients with AML1/ETO (+) acute myeloid leukemia].
This study was purposed to analyse the clinical efficacy of autologous peripheral blood stem cell transplantation (APBSCT) in 13 Patients with AML1/ETO (+) acute myeloid leukemia, and to evaluate the role of quantitative detecting the AML1/ETO gene in treatment of AML patients. A total of 13 patients with AML1/ETO (+) acute myeloid leukemia treated with APBSCT from August 2007 to November 2012 were retrospectively analyzed. The median follow-up time was 26 (7.8-75.8)months. Kaplan-Meier analysis was used to calculate the overall survival (OS), leukemia-free survival (LFS) and cumulative relapse rate (RR). Log rank method was used to perform univariate analysis. The results showed that the 3 year-OS, LFS, and RR were (70.5 ± 15.3)%, (51.3 ± 16.7)%, 48.7%, respectively. The AML1/ETO expression level in 4 cases out of 5 relapsed patients was quantified during and after therapy, and the result showed that AML1/ETO expression level significantly increased before morphological relapse. In univariate analysis, there was no statistic significance in terms of age, sex, count of white blood cells at diagnosis, interval from diagnosis to transplantation, count of MNC for infusion. It is concluded that APBSCT has good therapeutic effect on AML1/ETO (+) AML, and regular quantitative monitoring of AML1/ETO expression level can predict early recurrence. Allogeneic hematopoietic stem cell transplantation after relapse may contribute to obtain opportunity to achieve the long-term survival for intermediate and high risk patients.
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
Qing-Yi
QY
Zhang
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
Wen-Rong
WR
Huang
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
Li-Ping
LP
Dou
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
Ai-Ling
AL
Deng
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
Lin
L
Fu
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
Yi-Han
YH
Xu
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
Zhan-Xiang
ZX
Liu
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
Yong-Hui
YH
Li
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
Nan
N
Wang
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China. E-mail: chunhuiliyu@yahoo.com.
Li
L
Yu
D000293:Adolescent; D000328:Adult; D002891:Chromosomes, Human, Pair 21; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D036102:Peripheral Blood Stem Cell Transplantation; D000075142:RUNX1 Translocation Partner 1 Protein; D014182:Transplantation, Autologous; D055815:Young Adult
C107844:AML1-ETO fusion protein, human; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; D000075142:RUNX1 Translocation Partner 1 Protein